Abstract: Objective：To investigate the expression and clinical value of CD24 in ovarian cancer． Methods: Data about CD24 expression in ovarian cancer were retrieved from the Oncomine database, then the prognostic value of CD24 was retrieved from an online survival analysis tool "Kaplan-Meier Plotter" (KM plotter) database. Results: For different types of cancer in Oncomine, there were 353 studies concerning expression of CD24, of which 64 studies were of statistically significance (41 up-regulated and 23 down-regulated). 5 149 samples of 7 studies assessed the expression of CD24 in ovarian cancer tissues and normal tissues. The expression of CD24 was significantly higher in the ovarian cancer tissue compared with the normal tissues (P＜0.05). And negatively associated with the overall survival rate (P＜0.05). Subgroup analysis revealed that CD24 expression showed negative relation to the prognosis of ovarian endometrioid adenocarcinoma patients and ovarian serous cystadenocarcinoma patients. Conclusions: CD24 is overexpression in ovarian cancer and negatively associated with the overall survival rate, which may be used as an important target of medication for ovarian cancer．

Key words: Ovarian cancer, Oncomine, cluster of differentiation 24 (CD24), survival analysis